Glioblastoma Multiforme Treatment Advances: From Standard Care to Emerging Therapies
Glioblastoma multiforme (GBM) remains one of the most aggressive and treatment-resistant cancers of the central nervous system. Despite decades of research, median survival for patients continues to hover around 12–15 months following diagnosis. However, a wave of innovation across surgical technique, radiation delivery, immunotherapy, and targeted molecular agents is reshaping how...
0 Comments 0 Shares 374 Views 0 Reviews